The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Abstract
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours 1,2. We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma-in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733). We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma. Clinical responses are accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens. The antigen-specific cytotoxic T-cell responses in some responders reach magnitudes typically reported for adoptive T-cell therapy, and are durable. Our findings indicate that RNA-LPX vaccination is a potent immunotherapy in patients with CPI-experienced melanoma, and suggest the general utility of non-mutant shared tumour antigens as targets for cancer vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [18]
In the citing paper
“Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.345,350–352”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [345]
In the citing paper
“For example, FixVac, which was developed based on the RNA-LPX formulation, is a systemic mRNA vaccine encoding four non-mutated antigens of melanoma200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“After the eighth immunization, more than 75% of patients generated immune responses against at least one tumour-associated antigen, and CD8+ T cells played a major role in high-magnitude T cell responses200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“Moreover, a combination of FixVac/anti-programmed cell death protein 1 (PD1) antibody augmented the antitumour effect of FixVac, resulting in a >35% tumour regression rate in immune checkpoint inhibitor-experienced patients200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“The interim analysis from the phase I trial (NCT02410733) showed that the metabolic activity of the spleen increased post the sixth immunization, indicating targeted delivery of FixVac and activation of resident immune cells200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationMiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavskii, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,730
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Macrophage-Mediated Cancer Immunology in Cutaneous Malignancies
Komine, M. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_153
Cirella, A., Bolaños, E., Trani, C. A. D., de Andrea, C. E., Sánchez‐Gregorio, S., Etxeberría, I., González-Gomariz, J., Olivera, I., Brocco, D., Glez‐Vaz, J., et al. (2023) · doi:10.1158/2326-6066.c.6551084
CD169 targeting liposomes, a cancer vaccine that delivers.
Grabowska, J. A. (2023) · doi:10.5463/thesis.223
Vaccines and active immunization against cancer
Rojas, L. A., & Balachandran, V. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87763-3.00018-6 · Cited by 1
Weiner, D. B., Jansen, K. U., & Villafana, T. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00068-2
mRNA vaccine encoding neoantigen for cancer immunotherapy using mouse melanoma as a model
Sittplangkoon, C., & Palaga, T. (2021) · Chula Digiverse · doi:10.58837/chula.the.2021.23
Rubins, S., & Рубинс, А. (2023) · Springer eBooks · doi:10.1007/978-3-031-15130-9_104
Détournement d’une bactérie commensale pour la vaccination anti-tumorale
Mabrouk, N., Méjean, F., Tanchot, C., & Tartour, É. (2023) · médecine/sciences · doi:10.1051/medsci/2023115
Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 for Therapeutic Gene Correction
Walther, J. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/2032
Комісаренко, С. В., & Романюк, С. И. (2023) · Visnik Nacional noi academii nauk Ukrai ni · doi:10.15407/visn2023.12.003
The principles of neoplasia and oncology
Turnquist, C., Taylor, T. R., Al‐Mossawi, H., & Watson, R. A. (2024) · Surgery (Oxford) · doi:10.1016/j.mpsur.2023.12.002
Jiskoot, W., Kersten, G. F. A., Mastrobattista, E., & Slütter, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_15
RNA therapies and medicines – general overview and pharmacological challenges
Mutafova, I., Handjieva‐Darlenska, T., Georgiev, K., Minchev, V. T., & Belcheva, V. (2023) · Annual for Hospital Pharmacy · doi:10.14748/ahp.v9i1.9240
PET-Bildgebung bei der Entwicklung von mRNA-Vakzinen
Miederer, M. (2024) · Angewandte Nuklearmedizin · doi:10.1055/a-2145-1017
Self-citationImmuntherapie bei gastrointestinalen Tumoren
Stocker, G., Hacker, U. T., & Lordick, F. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2060-2192
RETRACTED CHAPTER: Lymphoma Vaccines: Background and Perspectives
Wölfel, T. (2024) · Cancer immunotherapy · doi:10.1007/13905_2024_45
RetractedDiscovery of T Cell Epitopes for Cancer Immunotherapy
Zuleger, G., Krackhardt, A. M., & Hiltensperger, M. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_221
mRNA Vaccination for Breast Cancer
Schmidt, M., & Sahin, U. (2024) · Cancer immunotherapy · doi:10.1007/13905_2024_46
Self-citationmRNA-based cancer therapeutics
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00006-6
Khatami, F., Zahedian, S., Baghdadabad, L. Z., Mashhadi, R., Hasanzad, M., Ahadi, Z., & Aghamir, S. M. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-4974-4_10
Johansen, P., Flory, S., Šošić, L., Kündig, T. M., & Lang, C. C. (2024) · Journal of Dermatology Research · doi:10.46889/jdr.2024.5310
Advances in the development of therapeutic mRNA vaccines for cancer therapy
Deng, K., Li, X., Liu, W., Liu, J., Wang, R., Yin, Y., & Zhang, C. Y. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0878
Cancer Vaccines Based on mRNA: Hype or Hope?
de Mey, W., Autaers, D., Bertazzon, G., Esprit, A., Aragon, M. M., Franceschini, L., & Breckpot, K. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch13
Circular RNA Therapeutics and Vaccines
Liu, X., & Zhu, G. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch5
mRNA vaccines: The new frontier
Yan, Z., Yang, M. J., Tian, E., & Lai, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00021-8
Antibodies Against Melanoma Antigens – Clinical and Therapeutical Markers
Neagu, M. T., Constantin, C., Dobre, E.-G., & Zurac, S. A. (2025) · Journal of Dermatology Research · doi:10.46889/jdr.2025.6105
Recent Advances in Biomaterials for Immunotherapeutic Applications
Shukla, A. K., Tiwari, A., Anitha, K., Yadav, V. K., Yadav, V. P., Kumar, S., Mishra, M. K., Kumar, M., & Dev, S. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-7022-9_4
Single-use bags as a viable solution for long-term stability of lipid nanoparticles
Takeda, Y. S., Wang, F., Gu, X., Delaunay, L., & Akbari, S. (2025) · Physics of Fluids · doi:10.1063/5.0257548
Immunophenotyping of colon cancer for identification of potential antigens for colon cancer vaccines
Wang, X., Lai, J., Wang, D., Wei, K., & Yang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1403256
Practical Clinical Approaches Used in RNA-Based Therapeutics
Moar, K., Pushpa, Kumar, R. S., & Maurya, P. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-3456-9_12
Bene, A. D., D’Aniello, A., Mottola, S., Mazzarella, V., Cutolo, R., Campagna, E., Benedetti, R., Altucci, L., Cosconati, S., Maro, S. D., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00032g
A comprehensive review of anticancer drug therapy: Advances and challenges
Mohammed, S. A., Kadhim, A. J., & Hussein, M. S. (2025) · International Journal of Pharmaceutical and Clinical Research · doi:10.33545/26647591.2024.v6.i2a.115
In situ therapeutic vaccines for leukemia by chemo-nanoadjuvant therapy
Zhang, P., Cui, G., Wang, T., Zhao, X., Wang, X., Ye, R., Liu, T., Zheng, Y., & Zhong, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113851
CD4+ T cells in Antitumour Immunity
Bawden, E., & Gebhardt, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00187-3
Heil, J., Sander, S., & Martens, U. M. (2025) · Forum · doi:10.1007/s12312-025-01462-w
Novel approaches to immuno-oncology
Chen, R., & Su, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00047-3
Development Of mRNA Vaccines And Therapeutics Beyond Covid-19
Yadav, A., Dwivedi, A., & Darwhekar, G. N. (2025) · European journal of parenteral & pharmaceutical sciences · doi:10.37521/ejpps30211
Immunologische Grundlagen der Immunonkologie
Wölfel, T. (2025) · Die Onkologie · doi:10.1007/s00761-025-01791-4
Bergada, C. B., Song, P., Knudsen, K. B., Jaynes, C. L., Leuvenink, H. G. D., Llorente, V. R., van Furth, L. A., Hager, H., Nørregaard, R., Hillebrands, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.28.672793
Personalized Cancer Vaccines Targeting Neoantigens
Himuro, H., & Sasada, T. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_291
Immunotherapy for Cutaneous Melanoma
Soleymanitabar, A., Keshavarz‐Fathi, M., Hargadon, K. M., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_237
Ma, B., Hu, H., Lin, Y., Wang, Z., & Song, Q. (2025) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2025.100365
Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy
Millar, L., Barros, R. D. M., Kapiris, M., Nikolaou, C., Gerlinger, M., & Wu, Y. (2025) · Clinical & Experimental Immunology · doi:10.1093/cei/uxaf073
A battery-free, chipless, soft nanofluidic intracellular delivery patch for internal organsPreprint
Yu, C., Li, M., Chang, L., Yu, X., Yin, D., Wang, P., Hao, Y., Yue, W., Yao, K., Wang, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2154899/v1
Miederer, M., Pektor, S., Miederer, I., Bausbacher, N., Keil, I. S., Hefesha, H., Haas, H., Sahin, U., & Diken, M. (2021) · Figshare · doi:10.6084/m9.figshare.13888978
Self-citationWang, S., Chen, L., & Liu, W. (2022) · Figshare · doi:10.6084/m9.figshare.21332914
Wang, S., Chen, L., & Liu, W. (2022) · Figshare · doi:10.6084/m9.figshare.21332911
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.26690719
Wang, S., Chen, L., & Liu, W. (2022) · Figshare · doi:10.6084/m9.figshare.21332893
Wang, S., Chen, L., & Liu, W. (2022) · Figshare · doi:10.6084/m9.figshare.21332908
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.26690725
Wang, S., Chen, L., & Liu, W. (2022) · Figshare · doi:10.6084/m9.figshare.21332899
Wang, S., Chen, L., & Liu, W. (2022) · Figshare · doi:10.6084/m9.figshare.21332905
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.25374844
Trivedi, V. S., Yang, C., Klippel, K., Yegorov, O., Roemeling, C. A. V., Hoang-Minh, L., Fenton, G., Ogando‐Rivas, E., Castillo, P., Moore, G. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25059573
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.26690722
Trivedi, V. S., Yang, C., Klippel, K., Yegorov, O., Roemeling, C. A. V., Hoang-Minh, L., Fenton, G., Ogando‐Rivas, E., Castillo, P., Moore, G. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25059438
Trivedi, V. S., Yang, C., Klippel, K., Yegorov, O., Roemeling, C. A. V., Hoang-Minh, L., Fenton, G., Ogando‐Rivas, E., Castillo, P., Moore, G. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26672109
Wang, S., Chen, L., & Liu, W. (2022) · Figshare · doi:10.6084/m9.figshare.21332902
Wang, S., Chen, L., & Liu, W. (2022) · Figshare · doi:10.6084/m9.figshare.21332896
Deng, B., Ma, B., Ma, Y., Cao, P., Leng, X., Huang, P., Zhao, Y., Ji, T., Lu, X., & 刘兰霞 (2022) · Figshare · doi:10.6084/m9.figshare.19386700
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.25374741
Individualized Medicine for Cardiovascular Disease: The curATime Consortium
Cate, V. T., & Wild, P. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-93623-4_8
mRNA-based vaccines: Rational antigen design, delivery optimization, and immune modulation
Liu, S., Shi, H., Dai, D., Tian, T., Duan, X., Sun, J., Xu, W., Yin, X., Xie, Y., & Song, X. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112312
Pre-Existing Immunity Shapes Cancer Immunotherapy Efficacy
Xagara, A., Koinis, F., Tsapakidis, K., Samaras, I., Chantzara, E., Vasilieva, K., Lazarou, A., Georgoulias, V., & Kotsakis, A. P. (2026) · Onco · doi:10.3390/onco6010004
Intranasal circRNA vaccine elicits localized and safer antitumor immunity
Jiang, Z., Ke, Y., & Peng, Y. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2026.01.001
An overview of the mRNA applications and their therapeutic functions in clinical development
Ramakrishnaiah, T. N., Srikar, K. S., Deb, A., Ahmed, K. S., Chandraghatgi, R. R., Sarin, Y., Roopini, K., & Rajashekara, S. (2026) · Next research. · doi:10.1016/j.nexres.2026.101413
Ravishankar, S., Bhavya, E., Boopathy, N., Sakthivel, S. R., Sekar, S., Murugathirumal, A., & Nandakumar, K. (2026) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0076
Targeting store-operated Ca2+ entry as a novel strategy to overcome treatment resistance in melanoma
Gutiérrez, D. M. V., Niemeyer, B. A., Kreis, S., & Bréchard, S. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189548
Personalized mRNA Cancer Vaccines: Advances, Limitations, and the Promise of mRNA-4157 (V940)
Pan, D. C. (2026) · International Journal of Biology and Life Sciences · doi:10.54097/dg93xg63
Fabien, G., Dusingizimana, T., & Al-Dubai, A. (2026) · doi:10.69739/jfsh.v1i1.1526
Cao, S., Bai, G., Wuri, Q., Li, J., Zhang, X., Han, Z., Wu, H., Wu, J., Wang, C., Yu, X., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27042039
Chen, R., Ma, Q., Pan, Y. Q., Zhang, T., Zhang, Z., Di, C., & Ran, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1747607
Lipid nanoparticles–mRNA platforms: Advancing cancer immunotherapy
Aadil, K. R., Bhange, K., Kumar, N., Jha, A., & Mishra, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00005-7
Auni, N. M. A. N. A., Redzwan, N. M., Hussain, F. A., Yahya, M. M., Hamid, S. S. A., & Wong, K. K. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116459
Ninmer, E. K., Zhu, H., Sarkar, A., Chianese‐Bullock, K. A., Ross, M. I., Haas, N. B., von Mehren, M., Boisvert, M. E., Kirkwood, J. M., & Slingluff, C. L. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4606
Zhang, L., Zhang, Q., Zhang, X., Mao, A., Liu, Y., & Luo, H. (2026) · MedComm – Future Medicine · doi:10.1002/mef2.70051
Current perspectives of nanovaccines and nanomedicines in cancer treatment
Butt, A., Noor, A., & Din, F. U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44579-8.00010-2
Cancer immunotherapy : efficacy and safety of a melanin-based vaccine
Cuzzubbo, S. (2021) · theses.fr (ABES) · doi:10.70675/2e1d38a6z8d99z458dza769zb7bccda2b709
Impact de la radiothérapie interne vectorisée alpha sur le microenvironnement tumoral
Perrin, J. (2021) · theses.fr (ABES) · doi:10.70675/31c91866z101fz4e07zbde2z6887a8fdba6d
Mohammadi, A. (2026) · Discover Oncology · doi:10.1007/s12672-026-04956-8
In Vivo Messenger Ribonucleic Acid Vaccines: Advances and Future Directions
Nowzari, F., Zanjani, M., Samimi, K., Zahedi, M., Kian, M., Tanideh, R., Dorali-nabi, H., & Tanideh, N. (2025) · West Kazakhstan Regenerative Medicine Journal · doi:10.4103/wkrj.wkrj_7_26
Wang, T., Mei, Y., Liu, S., Wang, H., Chen, M., & Han, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778522
Therapeutic cancer vaccines: navigating clinical translation and multimodal synergy
Chu, T.-H., Huynh, T. L., & Phuong, L.-T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1818121
The MYB-related transcription factor MYPOP acts as a selective regulator of cancer cell growth
Strunk, J., Hüppner, A., Sial, M., Plath, M., Sheriff, M. B., Wagner, S., Freitag, K., Mikuličić, S., Döring, T., Bopp, T., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10272-2 · Cited by 1
Self-citationCamarena, M. E., Vara, C., Papadopoulos, C., Montañés, J. C., Razquin-Sola, S., Taillandier-Coindard, M., Pak, H., Müller, M., Khelgati, N., García-Soriano, J. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.725836
Advances in RNA-Based Therapeutics in Oncology
Lopes-Cardoso, H., Panão-Costa, J., Amaral, A. T., Soares-Gonçalves, J., Neves, B. F., Voronovska, A., Batista, A., Biscaia-Caleiras, M., Fonseca, N. A., Simões, S., et al. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_19
Kanaan, M. H. G., Lee, B. M., Abdullah, S. S., Park, C., Ghasemian, A., & Mudenda, S. (2026) · Cell and Tissue Biology · doi:10.1134/s1990519x26600201
Cancer vaccines: comprehensive review
Clifford, R. E., Manu, N., Yang, Q., Arif, Z., Aggen, D. H., Bryan, M. E., Gupta, A., Shaw, H. M., Church, D., Corrie, P. G., et al. (2026) · BJS Open · doi:10.1093/bjsopen/zrag041
CAR-T cells and cancer nanovaccines: Comparative insights into advances and translational challenges
Zaccariotto, G. D. C., & Zucolotto, V. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108942
Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions
Altay, H., Al-Hashimi, I., Matthews, J., DeAlessandro, G., & Ghelani, G. H. (2026) · Vaccines · doi:10.3390/vaccines14060497
Identification of tumor-associated antigens with multi-cancer therapeutic potential
Wickland, D. P., Jessen, E., Nair, A., Necela, B. M., Lauer, K., Mangalaparthi, K. K., Balaya, R. D. A., Pandey, A., Mansfield, A. S., Knutson, K. L., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1839980 · Cited by 1
Tian, S., Wang, J., Yu, Y., Liu, Y. G., Liu, Y. G., Li, J., Shang, Y., Zhao, Y., Zhang, Y., Fang, Y., et al. (2026) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2026.101170
Vaccines as treatment for melanoma: an update review
Zhang, J., Cao, Q., Cen, Y., Zhang, L., & Chen, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1724490 · Cited by 1
Programming the immunological properties of mRNA vaccines for cancer
Wu, A., Jeong, S. D., Schrank, B. R., Kim, B. Y. S., Sharma, P., & Jiang, W. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01316-z · Cited by 1
Kellermann, G., Croce, O., Mograbi, B., Hofman, P. M., & Brest, P. (2026) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqag060
Metadata
- Authors
- Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., Tolliver, C., Caspar, J., Quinkhardt, J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M., Müller, V., Mitzel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann, R., Hassel, J. C., Loquai, C., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- University Hospital Frankfurt (DE)
- ORCID
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 585
- Issue
- 7823
- Pages
- 107-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3046115489
- Cited by
- 1,052
- References
- 36
- Citations by year
- 2026: 140 · 2025: 204 · 2024: 191 · 2023: 190 · 2022: 174 · 2021: 131 · 2020: 21
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- RNA vaccines, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, tumor-associated antigens, cancer immunotherapy, CD4+ T cells, CD8+ T cells, cytotoxic T lymphocyte response
- MeSH terms
- Antigens, Neoplasm, Antineoplastic Agents, Combined Modality Therapy, Humans, Melanoma, Neoplasm Staging, RNA, Neoplasm, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Vaccination, Cancer Vaccines, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
